Mechanisms of gene therapy for tolerance: B7 signaling is required for peptide-IgG gene-transferred tolerance induction

Journal of Immunology

Volumn 175, Issue 2, 2005, Pages 780-787

  Litzinger, Mary T ^a,b,d   Su, Yan ^a,b,c   Lei, Tie Chi ^b,c   Soukhareva, Nadejda ^b,c   Scott, David W ^a,b,c  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b HOLLAND LABORATORY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; FAS LIGAND; HYBRID PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE ACTIVATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE THERAPY; GENE TRANSFER; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SPLEEN CELL;

EID: 23244454645     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.2.780     Document Type: Article

References (30)

1. Scott, D. W., M. Venkataraman, and J. J. Jandinski. 1979. Multiple pathways of B lymphocyte tolerance. Immunol. Rev. 43: 241-280.
2. Zambidis, E. T., and D. W. Scott. 1996. Epitope-specific tolerance induction with an engineered immunoglobulin. Proc. Natl. Acad. Sci. USA 93: 5019-5024.
3. Zambidis, E. T., R. K. Barth, and D. W. Scott. 1997. Both resting and activated B lymphocytes expressing engineered peptide-Ig molecules serve as highly efficient tolerogenic vehicles in immunocompetent adult recipients. J. Immunol. 158: 2174-2182.
4. Zambidis, E. T., A. Kurup, and D. W. Scott. 1997. Genetically transferred central and peripheral immune tolerance via retroviral-mediated expression of immunogenic epitopes in hematopoietic progenitors or peripheral B lymphocytes. Mol. Med. 3: 212-224.
5. Melo, M. E. F., J. Qian, M. El-Amine, R. K. Agarwal, N. Soukhareva, Y. Kang, and D, W. Scott. 2002. Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J. Immunol. 168: 4788-4795.
6. Xu, B., and D. W. Scott. 2004. A novel retroviral gene therapy approach to inhibit specific antibody production and suppress experimental autoimmune encephalomyelitis induced by MOG and MBP. Clin. Immunol. 111: 47-52.
7. Song, L., J. Wang, R. Wang, M. Yu, Y. Sun, G. Han, H. Chang, J. Qian, D. W. Scott, and B. Shen. 2004. B-cell delivery of GAD-Ig fusion construct induces specific tolerance and prevents diabetes in NOD mice: role of CD4 regulatory cells and TGF-β. Gene Ther. 11: 1487-1496.
8. Agarwal, R. K., Y. Kang, E. Zambidis, D. W. Scott, C. Chan, and R. R. Caspi. 2000. Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J. Clin. Invest. 106: 245-252.
9. Lei, T. C., and D. W. Scott. 2005. Induction of tolerance to fVIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B-cells as Ig fusion proteins. Blood 105: 4865-4870.
10. Eynon, E. E., and D. C. Parker. 1992. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J. Exp. Med. 175: 131-138.
11. Fuchs, E., and P. Matzinger. 1992. B cells turn off virgin but not memory T cells. Science 258: 1156-1159.
12. Gilbert, K. M., and W. O. Weigle. 1994. Tolerogenicity of resting and activated B cells. J. Exp. Med. 179: 249-258.
13. El-Amine, M., M. Melo, Y. Kang, H. Nguyen, J. Qian, and D. W. Scott. 2000. Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells. J. Immunol. 165: 5631-5636.
14. El-Amine, M., M. Litzinger, M. E. F. Melo, and D. W. Scott. 2005. Gene therapy-based approach for immune tolerance induction using recombinant immunoglobulin carriers. In Gene Therapy of Autoimmune Disease. C. Prudhomme, ed. Kluwer Academic/Plenum Publishers, Eureka, New York, p. 101-111.
15. Hahne, M., T. Renno, M. Schroeter, M. Irmler, L. French, T. Bornand, H, R. MacDonald, and J. Tschopp. 1996. Activated B cells express functional Fas ligand. Eur. J. Immunol. 26: 721-724.
16. Tian, J., D. Zekzer, L. Hanssen, Y. Lu, A. Olcott, and D. L. Kaufman. 2001. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J. Immunol. 167: 1081-1089.
17. Gourley, T. S., D. R. Patel, K. Nickerson, S.-C. Hong, and C.-H. Chang. 2002. Aberrant expression of Fas ligand in mice deficient for the MHC class II trans-activator. J. Immunol. 168: 4414-4419.
18. Kang, Y., M. Melo, E. Deng, R. Tisch, M. El-Amine, and D. W. Scott. 1999. Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness. Proc. Natl. Acad. Sci. USA 96: 8609-8614.
19. El-Amine, M., J. A. Hinshaw, and D. W. Scott. 2002. In vivo induction of tolerance by an Ig peptide is not affected by the deletion of FcR or a mutated IgG Fc fragment. Int. Immunol. 14: 761-766.
20. Chiller, J. M., G. S. Habicht, and W. O. Weigle. 1971. Kinetic differences in unresponsiveness of thymus and bone marrow cells. Science 171: 813-815.
21. Sprent, J., and D. F. Tough. 1994. Lymphocyte life-span and memory. Science 265: 1395-1400.
22. Allison, J. P., C. Chambers, A. Hurwitz, T. Sullivan, B. Boitel, S. Fournier, M. Brunner, and M. Krummel. 1998. A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Novarris Found. Symp. 215: 92-98.
23. Freeman, G. J., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X.-Y. Ke, P. D. Rennert, G. S. Gray, J. G. Gribben, and L. M. Nadler. 1995. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2: 523-532.
24. Kuchroo, V. K., M. Prabhu Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 80: 707-718.
25. Ranger, A. M., M. Prabhu Das, V. K. Kuchroo, and L. H. Glimcher. 1996. B7-2 (CD86) is essential for the development of IL-4-producing T cells. Int. Immunol. 8: 1549-1560.
26. Salomon, B., and J. A. Bluestone. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Ann. Rev. Immunol. 19: 225-252.
27. Perez, V. L., L. Van Parijs, A. Biuckians, X. X. Zheng, T. B. Strom, and A. K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6: 411-417.
28. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431-440.
29. Lohr, J., B. Knoechel, S. Jiang, A. H. Sharpe, and A. K. Abbas. 2003. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat. Immunol 4: 664-669.
30. Lohr J., B. Knoechel, E. C. Kahn, and A. K. Abbas. 2004. Role of B7 in T cell tolerance. J. Immunol. 173: 5028-5035.